Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has reported positive final analysis results from the Phase III clinical trial of KN046 for sq NSCLC, showing statistically significant improvement in overall survival and progression-free survival when combined with chemotherapy. Despite the promising results, the company cautions that there is no guarantee for the regulatory approval of KN046. Investors are encouraged to approach the company’s shares with caution as further research updates are anticipated to be shared at industry conferences.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
